[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592419":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":38,"locations":48,"responsibleParty":64,"collaborators":11,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":11,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":11,"enrollmentInfo":76,"targetDuration":11,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":11,"overallStatus":85,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL",null,[13,14,15,16],"Drug: DA-5222","Drug: DA-5222-R1","Drug: DA-5222-R2","Drug: DA-5222-R3",{"label":18,"type":10,"description":11,"interventionNames":19},"Sequence B",[13,14,15,16],[21,26,30,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","DA-5222","single dose administration (DA-5222 one tablet once a day)",[9,18],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"DA-5222-R1","single dose administration (DA-5222-R1 one tablet once a day)",[9,18],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"DA-5222-R2","single dose administration (DA-5222-R2 one tablet once a day)",[9,18],{"type":22,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"DA-5222-R3","single dose administration (DA-5222-R3 one tablet once a day)",[9,18],[39,44],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"Jihyun Sung","CONTACT","+82-02-920-8369","jhsung@donga.co.kr",{"name":45,"role":41,"phone":46,"phoneExt":11,"email":47},"Heechan Jung","+82-02-920-8322","hcjung@donga.co.kr",[49],{"facility":50,"status":11,"city":51,"state":52,"zip":53,"country":52,"countryCode":11,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Bumin Hospital","Seoul","South Korea","07590",{"type":55,"coordinates":56},"Point",[57,58],126.9784,37.566,{"lat":58,"lon":57},[61],{"name":62,"role":41,"phone":11,"phoneExt":11,"email":63},"Taegon Hong, Ph.D","tghong@bumin.co.kr",{"type":65,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100592419","phase-1-clinical-trial-of-comparing-da-5222-single-administration-and-co-administration-of-da-5222-r1-da-5222-r2-and-da-5222-r3-in-healthy-adult-subjects-100592419",false,"NCT06993181","Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy volunteers\n* BMI between 18 and 30 kg\u002Fm2\n* Body weight: Male≥50kg, Female≥45kg\n* Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study\n\nExclusion Criteria:\n\n* Subjects with clinically significant medical history\n* Subjects with history of drug abuse or addicted\n* Subjects with allergy or drug hypersensitivity",true,"ALL","19 Years",{"count":77,"type":78},48,"ESTIMATED","INTERVENTIONAL",[81],"PHASE1","This study is to compare pharmacokinetics and safety profiles of DA-5222 single-administration and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects",[84],"Healthy","NOT_YET_RECRUITING","2025-06-03",{"date":88,"type":89},"2025-06-06","ACTUAL",{"date":91,"type":78},"2025-06",{"date":93,"type":78},"2025-07",{"name":5,"class":6},1]